MetaVia Unveils Positive Phase 1 Study Results for DA-1726 at EASL Congress 2026#None#Barcelona#MetaVia#DA-1726#EASL_Congress
MetaVia Unveils Positive Phase 1 Study Results for DA-1726 at EASL Congress 2026
MetaVia's DA-1726 shows promising Phase 1 results at EASL 2026, achieving significant weight loss and liver improvement signs in obesity treatment.
third-news.com
May 27, 2026 at 12:49 PM
MetaVia Unveils Positive Phase 1 Study Results for DA-1726 at EASL Congress 2026#None#Barcelona#MetaVia#DA-1726#EASL_Congress
Exploring the Innovative DA-1726: A Breakthrough GLP-1 Dual Agonist Presentation at EASL 2026#United_States#Cambridge#MetaVia#DA-1726#EASL_Congress
Exploring the Innovative DA-1726: A Breakthrough GLP-1 Dual Agonist Presentation at EASL 2026
MetaVia Inc. is all set to present findings on DA-1726, a promising GLP-1 dual agonist, at the upcoming EASL Congress 2026 in Barcelona, Spain.
third-news.com
May 11, 2026 at 12:37 PM
Exploring the Innovative DA-1726: A Breakthrough GLP-1 Dual Agonist Presentation at EASL 2026#United_States#Cambridge#MetaVia#DA-1726#EASL_Congress
Groundbreaking Dual-Action Therapy CG-0416 Revolutionizes Obesity Management at 2025 EASL Congress#China#Shanghai#CureGene#EASL_Congress#CG-0416
Groundbreaking Dual-Action Therapy CG-0416 Revolutionizes Obesity Management at 2025 EASL Congress
At the 2025 EASL Congress, CureGene Pharmaceuticals revealed CG-0416, a pioneering dual-action therapy targeting obesity and liver health with remarkable efficacy.
third-news.com
May 17, 2025 at 12:53 AM
Groundbreaking Dual-Action Therapy CG-0416 Revolutionizes Obesity Management at 2025 EASL Congress#China#Shanghai#CureGene#EASL_Congress#CG-0416
AusperBio Showcases Promising Clinical Data for AHB-137 During EASL Congress 2025#United_States#San_Francisco#AusperBio#AHB-137#EASL_Congress
AusperBio Showcases Promising Clinical Data for AHB-137 During EASL Congress 2025
AusperBio Therapeutics presents significant interim data for AHB-137 at the EASL Congress 2025, spotlighting its potential in hepatitis B treatment.
third-news.com
May 7, 2025 at 7:08 PM
AusperBio Showcases Promising Clinical Data for AHB-137 During EASL Congress 2025#United_States#San_Francisco#AusperBio#AHB-137#EASL_Congress
MetaVia Inc. to Present Late-Breaking Data on DA-1241 at EASL Congress 2025#USA#Cambridge#MetaVia#DA-1241#EASL_Congress
MetaVia Inc. to Present Late-Breaking Data on DA-1241 at EASL Congress 2025
MetaVia Inc. will unveil data from its Phase 2a trial on DA-1241, a novel treatment for metabolic diseases, at the EASL Congress 2025 in Amsterdam.
third-news.com
April 23, 2025 at 1:02 PM
MetaVia Inc. to Present Late-Breaking Data on DA-1241 at EASL Congress 2025#USA#Cambridge#MetaVia#DA-1241#EASL_Congress